Bronnen:
- Aladul MI, Fitzpatrick RW, Chapman SR. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs. 2017;31:533-44.,Aladul MI, Fitzpatrick RW, Chapman SR. Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs. 2017;31:439-46